StreetAlpha.app
Home › Stocks › AMLX

Amylyx Pharmaceuticals, Inc. (AMLX)

Healthcare
$26.02
▼ −0.69%
LAST CLOSE · NOV 20

Amylyx Pharmaceuticals develops drug candidates for endocrine conditions and neurodegenerative diseases, based in Cambridge, Massachusetts. It last closed at $26.02 on Nov 20, down 0.69% on the day. The next earnings report for AMLX is expected around Tue, Mar 2, 2027. For the quarter ended Sep 2026, AMLX reported EPS of -$0.38. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months AMLX insiders bought $152K of stock on the open market and sold $17.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is AMLX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AMLX.

Key Stats

Last 12 months
Results
Net income
−$163.2M
EPS (diluted)
−$1.43
Free cash flow
−$130.0M
Valuation
Market cap
$3.3B
128.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$240.1M
At Sep 30
Shareholder equity
$753.7M
Shares outstanding
128.6M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $285K$285KFY2021FY2022: $22.2M$22.2MFY2022FY2023: $380.8M$380.8MFY2023FY2024: $87.4M$87.4MFY2024FY2025: $0$0FY2025

From AMLX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · Time not announced
Reported EPS
-$0.38
Quarter ended Sep 2026
Year ago EPS
-$0.37
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.54Dec '24Mar 2025: -$0.42Mar '25Jun 2025: -$0.46Jun '25Sep 2025: -$0.37Sep '25Dec 2025: -$0.28Dec '25Mar 2026: -$0.37Mar '26Jun 2026: -$0.39Jun '26Sep 2026: -$0.38Sep '26Latest -$0.38
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How AMLX moved after its last 8 reports
Average move the session after a report ±5.8%
Nov 5, 2026Time not announced−6.0%
Aug 6, 2026Time not announced+10.7%
May 7, 2026Time not announced−5.3%
Mar 3, 2026Time not announced−7.8%
Nov 6, 2025Time not announced−5.9%
Aug 7, 2025Time not announced−4.3%
May 8, 2025Time not announced−6.0%
Mar 4, 2025Time not announced+0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AMLXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on AMLX: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 21Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on AMLX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AMLX

Technical Analysis

AMLX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 10% below its 20 day and 12% below its 50 day average. It is 19% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 39). The nearest support is the Pivot at $25.98, and the nearest resistance the Pivot R1 at $26.44.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.4%/day
Key levels
$41.1452 week high+58.1%
$29.0550 day average+11.6%
$28.6020 day average+9.9%
$28.60Swing high (Oct 9)+9.9%
$27.21100 day average+4.6%
$26.44Pivot R1+1.6%
$26.02Last close
$25.98Pivot−0.2%
$25.56Pivot S1−1.8%
$21.28Swing low (Aug 17)−18.2%
$21.12200 day average−18.8%
$10.8352 week low−58.4%
Indicators
RSI (14)38.90Weak, oversold below 30Neutral
MACD-0.46Below its signal lineBearish
Stochastic6.3Near the bottom of its rangeOversold
ADX (14)15.3No clear trend
Williams %R-92.1Oversold below −80, overbought above −20Oversold
CCI (20)-160.3Oversold below −100, overbought above 100Oversold
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$1.67Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for AMLX

What happened before

See how AMLX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AMLX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AMLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AMLXHow many large options trades hit AMLX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

AMLX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲168 buying vs 82 selling
  • ▲Held by funds +13.1 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding230207+11.1%
In funds' top 10125+140.0%
Held by funds102.9%89.8%+13.1 pts
New / increased59 / 10948 / 71+41.2%
Reduced / sold out45 / 3757 / 13+17.1%
Put/call ratio1.120.48+132.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AMLX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AMLX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$152K2 buys · 1 insider
Sold$17.3M26 sales · 6 insiders
49% of the selling was under pre-arranged trading plans.
2025-12 bought $101K2025-12 sold $94K2026-01 sold $4.0M2026-02 sold $606K2026-03 sold $1.2M2026-05 bought $51K2026-07 sold $539K2026-09 sold $2.9M2026-10 sold $831K2026-11 sold $7.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 10James M FratesCFOSale plan40,000$30.19$1.2M
Nov 9Joshua B CohenCo-CEOSale plan100,000$29.84$3.0M
Nov 9Justin B. KleeCo-CEOSale plan100,000$29.84$3.0M
Oct 5George M Milne JrDirectorSale plan30,000$27.70$831K
Sep 10Justin B. KleeCo-CEOSale30,464$32.18$980K
Sep 10Joshua B CohenCo-CEOSale30,464$32.19$981K
Every insider buy and sale for AMLX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AMLX insider trades →

From SEC Form 4 filings by AMLX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMLX is in one of them and how their past AMLX trades turned out.

AMLX in the AI portfolios
Loading…

AMLX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AMLX in an article yet. Here's the latest on the wider market.

AMLX in the news

AMLX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 16
Who traded AMLX · since 2022
Latest 1 filing
$1K – $15KTraded Oct 12, 2022Filed Nov 16, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KOct 12, 2022Nov 16, 202235 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a drug developer based in Cambridge, Massachusetts. The company is working on treatments for endocrine conditions and neurodegenerative diseases, many of them rare disorders with no approved treatments. Its lead candidate, avexitide, is being studied for a low blood sugar condition that can follow weight loss surgery. Its other programs target Wolfram syndrome, ALS and other rare diseases, with patients as the intended users of these treatments.

Headquarters
Cambridge, MA